NNMT Antibody (G-4): sc-376048

NNMT Antibody (G-4) is a mouse monoclonal IgG2a kappa light chain antibody that detects NNMT protein of mouse, rat, and human origin by western blotting (WB), immunoprecipitation (IP), immunofluorescence (IF), immunohistochemistry, and enzyme-linked immunosorbent assay (ELISA). NNMT Antibody (G-4) is available in both non-conjugated and various conjugated forms, including agarose, horseradish peroxidase (HRP), phycoerythrin (PE), fluorescein isothiocyanate (FITC), and multiple Alexa Fluor® conjugates. Nicotinamide N-methyltransferase (NNMT) plays a crucial role in the N-methylation of nicotinamide and other pyridines, which is essential for the metabolism of various compounds, including drugs and xenobiotics. NNMT activity in the human liver exhibits a bimodal frequency distribution, suggesting that genetic polymorphisms may influence NNMT function, leading to significant variations in individual responses to medications and susceptibility to toxicity. The human NNMT gene spans approximately 16.5 kilobases, consisting of three exons and two introns, and is located on chromosome 11q23.2. The isolated NNMT from human liver is 969 nucleotides long, with a 792 nucleotide open reading frame that encodes a 264 amino acid protein. The NNMT gene is considered a significant genetic determinant of plasma homocysteine levels, particularly in Spanish families, due to NNMT involvement in homocysteine metabolism.

Alexa Fluor^® is a trademark of Molecular Probes Inc., OR., USA

LI-COR^® and Odyssey^® are registered trademarks of LI-COR Biosciences

NNMT Antibody (G-4) References:

1. Human nicotinamide N-methyltransferase pharmacogenetics: gene sequence analysis and promoter characterization.  |  Yan, L., et al. 1999. Pharmacogenetics. 9: 307-16. PMID: 10471062
2. Expression of nicotinamide N-methyltransferase (E.C. 2.1.1.1) in the Parkinsonian brain.  |  Parsons, RB., et al. 2002. J Neuropathol Exp Neurol. 61: 111-24. PMID: 11853016
3. High expression of nicotinamide N-methyltransferase in patients with idiopathic Parkinson's disease.  |  Parsons, RB., et al. 2003. Neurosci Lett. 342: 13-6. PMID: 12727306
4. Enhanced expression of nicotinamide N-methyltransferase in human papillary thyroid carcinoma cells.  |  Xu, J., et al. 2003. J Clin Endocrinol Metab. 88: 4990-6. PMID: 14557485
5. Activation of nicotinamide N-methyltransferase gene promoter by hepatocyte nuclear factor-1beta in human papillary thyroid cancer cells.  |  Xu, J., et al. 2005. Mol Endocrinol. 19: 527-39. PMID: 15486044
6. Autotoxicity, methylation and a road to the prevention of Parkinson's disease.  |  Williams, AC. and Ramsden, DB. 2005. J Clin Neurosci. 12: 6-11. PMID: 15639403
7. Parkinson's disease: the first common neurological disease due to auto-intoxication?  |  Williams, AC., et al. 2005. QJM. 98: 215-26. PMID: 15728403
8. A genomewide exploration suggests a new candidate gene at chromosome 11q23 as the major determinant of plasma homocysteine levels: results from the GAIT project.  |  Souto, JC., et al. 2005. Am J Hum Genet. 76: 925-33. PMID: 15849667
9. Nicotinamide homeostasis: a xenobiotic pathway that is key to development and degenerative diseases.  |  Williams, AC. and Ramsden, DB. 2005. Med Hypotheses. 65: 353-62. PMID: 15922112
10. Identification of nicotinamide N-methyltransferase as a novel serum tumor marker for colorectal cancer.  |  Roessler, M., et al. 2005. Clin Cancer Res. 11: 6550-7. PMID: 16166432
11. Histone deacetylase inhibitor depsipeptide represses nicotinamide N-methyltransferase and hepatocyte nuclear factor-1beta gene expression in human papillary thyroid cancer cells.  |  Xu, J. and Hershman, JM. 2006. Thyroid. 16: 151-60. PMID: 16676400
12. Mouse nicotinamide N-methyltransferase gene: molecular cloning, structural characterization, and chromosomal localization.  |  Yan, L., et al. 1998. DNA Cell Biol. 17: 659-67. PMID: 9726248

Monoclonal antibodies for mammalian and non-mammalian protein targets represent essentially all targets covered by polyclonal antibodies. Over 8,300 of our antibodies are offered as ImmunoCruz^® conjugates which eliminates the need for a secondary antibody.

Santa Cruz Biotechnology antibodies have over 360,000 research citations. Anti-NNMT Antibody (G-4) has 12 citations in a variety of scientific publications.

Primary antibodies like Anti-NNMT Antibody (G-4) for mammalian target proteins are recommended for the detection of a range of mammalian species, primarily of mouse, rat and human species. Many mammalian antibodies are also ideal for veterinary research and reactive with ovine, porcine, caprine, feline, canine, bovine and equine protein targets. Santa Cruz Biotechnology primary monoclonal antibodies are suitable for laboratory research applications and are not intended for diagnostic or therapeutic use.

NNMT Antibody (G-4) Specifications

Alternate Product Name: NNMT

Product Clone Name: G-4

Classification: Primary Antibody

Clonality: Monoclonal Antibody

Antibody Isotype: IgG_2a kappa light chain

Amino Acids: 191-258

Epitope Target: NNMT

Epitope Species: human

Product Reactivity/Detection: NNMT

Species Reactivity/Detection: mouse, rat, human

Additional Mammalian Reactivity: N/A

Additional Non-Mammalian Reactivity: N/A

Applications: WB, IP, IF, IHC(P), ELISA

Vialing Information: Each vial contains 200 µg IgG_2a kappa light chain in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin

Research Citations: 12 citations in various scientific publications

Available Conjugates/Forms for NNMT Antibody (G-4): AC: Agarose, AF488: Alexa Fluor^® 488, AF546: Alexa Fluor^® 546, AF594: Alexa Fluor^® 594, AF647: Alexa Fluor^® 647, AF680: Alexa Fluor^® 680, AF790: Alexa Fluor^® 790, FITC: Fluoroscein, HRP: Horseradish Peroxidase, PE: Phycoerythrin, X: TransCruz Reagent